1155662-43-3 Usage
Description
(R)-3-methoxycarbonyl-(R)-5-methylpiperidine is a chiral chemical compound belonging to the class of piperidine alkaloids. It is characterized by its non-superimposable mirror image and the (R) prefix, which denotes its absolute configuration. (R)-3-methoxycarbonyl-(R)-5-methylpiperidine is known for its potential applications in the pharmaceutical industry, particularly in the synthesis of drugs for various therapeutic purposes.
Uses
Used in Pharmaceutical Industry:
(R)-3-methoxycarbonyl-(R)-5-methylpiperidine is used as a key building block for the synthesis of various drugs, including antiviral and antimalarial agents. Its unique structure and properties make it a valuable component in the development of new drug candidates.
Used in Antiviral Applications:
In the field of antiviral drug development, (R)-3-methoxycarbonyl-(R)-5-methylpiperidine is used as a starting material for the creation of new antiviral agents. Its structure allows for the design of compounds that can target specific viral proteins, potentially leading to the development of effective treatments for various viral infections.
Used in Antimalarial Applications:
(R)-3-methoxycarbonyl-(R)-5-methylpiperidine is also utilized in the development of antimalarial drugs. Its properties make it a promising candidate for the synthesis of compounds that can target the Plasmodium parasite, which is responsible for malaria. This could contribute to the development of novel treatments for this life-threatening disease.
Used in Drug Research and Development:
Due to its demonstrated pharmacological activities, (R)-3-methoxycarbonyl-(R)-5-methylpiperidine is an interesting target for further research and development in the pharmaceutical industry. Its potential applications in drug discovery make it a valuable compound for exploring new therapeutic options and advancing the field of medicinal chemistry.
Check Digit Verification of cas no
The CAS Registry Mumber 1155662-43-3 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,1,5,5,6,6 and 2 respectively; the second part has 2 digits, 4 and 3 respectively.
Calculate Digit Verification of CAS Registry Number 1155662-43:
(9*1)+(8*1)+(7*5)+(6*5)+(5*6)+(4*6)+(3*2)+(2*4)+(1*3)=153
153 % 10 = 3
So 1155662-43-3 is a valid CAS Registry Number.
1155662-43-3Relevant articles and documents
Continuous flow hydrogenation of functionalized pyridines
Irfan, Muhammed,Petricci, Elena,Glasnov, Toma N.,Taddei, Maurizio,Kappe, C. Oliver
, p. 1327 - 1334 (2009)
The heterogeneous hydrogenation of substituted pyridines has been accomplished by employing a continuous flow hydrogenation device that incorporates in situ hydrogen generation by electrolysis of H20 and pre-packed catalyst cartridges. In general, the hydrogenation reactions proceeded smoothly regardless of the supported precious metal catalyst (Pd/C, Pt/C, or Rh/C). By using 30-80 bar of hydrogen pressure at 60-80 °C full conversion was typically achieved in all cases at a flow rate of 0.5 mL min -1, providing the corresponding piperidines in high yields. For disubstituted pyr idines, variations in stereoselectivity were observed depending on both the metal catalyst and the temperature/ pressure of the hydrogenation reaction. For ethyl nicotinate the selectivity between partial and full hydrogenation could be tuned depending on the hydrogen pressure, solvent, and the choice of supported metal catalyst. Changing the hydrogen source from H20 to D2C) allowed the preparation of de-uteriated derivatives. Wiley-VCH Verlag GmbH & Co. KGaA.
N-ACYL PYRIDINE BIARYL COMPOUNDS AND THEIR USES
-
Page/Page column 155, (2012/08/08)
The present invention provides a compound of general formula:wherein Z2-Z6 include one or two nitrogen atoms as described herein, including pharmaceutically acceptable salts, enantiomers, stereoisomers, rotamers, tautomers, diastereomers, or racemates thereof. These compounds inhibit the activity of CDK9 and are thus useful as pharmaceuticals. Also provided are methods of treating a disease or condition mediated by CDK9 using the compounds of Formula I and isomers thereof, and pharmaceutical compositions comprising such compounds.
FUSED PYRAZOLE DERIVATIVES AS NOVEL ERK INHIBITORS
-
Page/Page column 100-101, (2012/04/04)
Disclosed are the ERK inhibitors of Formula (I): (Formula (I)) and the pharmaceutically acceptable salts thereof. All substitutents are as defined herein. Also disclosed are methods of treating cancer using the compounds of Formula (I).
